

Towards distributed manufacture of nanomedicines

Dai Hayward

Micropore Technologies Ltd
Wilton Centre
Redcar, TS10 4RF, UK
Dai.hayward@microporetech.com

As nanomedicines move from the urgency of mRNA vaccines, to minimise the impact of the Covid-19 pandemic, to other exciting nucleotide therapies two significant issues need to be addressed before nanomedicines become truly mainstream therapies; tissue targeting and robust scalability from discovery to manufacture.

This presentation will address the importance of resolving the latter issue as a means of imparting high levels of control, in a formulation agnostic manner, through which researchers and manufacturers are able to allow scale-appropriate optimisation of their formulations for therapeutic outcomes with no compromises.

Micropore Technologies' established approach to development and manufacture of a variety of nanoparticles will be discussed. A novel whole-process approach, unlocking a route to distributed manufacturing, will be described.